New Delhi, February 24 Eris Lifesciences announced on Tuesday that it has partnered with Natco Pharma for the commercialization of semaglutide in India.Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy for the management of Type 2 diabetes and chronic...